Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on March 17, 2025
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
GlobeNewswire
·
March 17, 2025
-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief …
BigCommerce Transforms Commerce Beyond Order Capture with Pipe17 Partnership
GlobeNewswire
·
March 17, 2025
AUSTIN, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors today announced a transformational partnership with …
Naval Air Systems Command Awards Follow-On Contractor Logistics Support & Engineering Services Contract Valued at up to $19.1 Million to Kratos Defense for the BQM-177A Subsonic Aerial Target System
GlobeNewswire
·
March 17, 2025
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Kratos Defense …
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
GlobeNewswire
·
March 17, 2025
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other …
Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25)
GlobeNewswire
·
March 17, 2025
BOSTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today …
Interstellar Communication Successfully Launches First icMercury Satellite via SpaceX
GlobeNewswire
·
March 17, 2025
Miami, FL, March 17, 2025 (GLOBE NEWSWIRE) -- Interstellar Communication Holdings Inc. (the “Company” or “Interstellar Communication”), celebrated a major milestone today with the successful launch of its first icMercury PocketQube satellite, HADES-ICM. …
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
GlobeNewswire
·
March 17, 2025
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration ( …
LifeVantage Expands Global Reach with International Launch of the MB System™
GlobeNewswire
·
March 17, 2025
SALT LAKE CITY, March 17, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody …
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
GlobeNewswire
·
March 17, 2025
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement …
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 17, 2025
-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 …
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
GlobeNewswire
·
March 17, 2025
Antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE …
Gradial Secures $13M to Build AI Marketing Operations Agents
GlobeNewswire
·
March 17, 2025
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Gradial, a pioneering AI startup transforming enterprise marketing operations with AI agents, today announced it has secured $13 million in Series A funding, bringing its total capital raised to nearly $20 …
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
GlobeNewswire
·
March 17, 2025
JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal …
Pakal Technologies Announces Commercial Shipments of Breakthrough Gen 2 650V IGTO(t) Power Semiconductor
GlobeNewswire
·
March 17, 2025
ATLANTA, March 17, 2025 (GLOBE NEWSWIRE) -- Today, Pakal Technologies, a leading next generation silicon power semiconductor company announces the commercial launch of its breakthrough 650V IGTO(t) power semiconductor at APEC, the Applied Power Electronics …
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 17, 2025
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social …
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
GlobeNewswire
·
March 17, 2025
New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE …
Sintx Technologies Announces Board Chairman Transition
GlobeNewswire
·
March 17, 2025
SALT LAKE CITY, Utah, March 17, 2025 (GLOBE NEWSWIRE) -- Sintx Technologies, Inc. (NASDAQ: SINT) (“Sintx” or the “Company”), a leader in advanced ceramics for medical device and technical applications, today announced that Dr. Sonny Bal has retired as …
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
GlobeNewswire
·
March 17, 2025
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement …
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
GlobeNewswire
·
March 17, 2025
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
MicroCloud Hologram Inc. Researches CV-QNN (Continuous Variable Quantum Neural Networks) Technology and Builds Variational Quantum Circuits Embedded in CV Architecture
GlobeNewswire
·
March 17, 2025
SHENZHEN, China, March 17, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the "Company"), a technology service provider, they are researching CV-QNN (Continuous Variable Quantum Neural Networks) technology, with the aim of …